• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Thursday's Pre-Market Session

    3/2/23 8:06:17 AM ET
    $APGN
    $ATXI
    $BPTS
    $BRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $APGN alert in real time by email

    Gainers

    • Biophytis (NASDAQ:BPTS) stock moved upwards by 34.1% to $0.56 during Thursday's pre-market session. The company's market cap stands at $11.4 million.
    • OncoSec Medical (NASDAQ:ONCS) shares rose 32.35% to $2.7. The market value of their outstanding shares is at $8.0 million.
    • Avenue Therapeutics (NASDAQ:ATXI) stock increased by 30.35% to $1.46. The market value of their outstanding shares is at $8.0 million.
    • BioRestorative Therapies (NASDAQ:BRTX) shares increased by 26.52% to $3.53. The company's market cap stands at $12.9 million.
    • Apexigen (NASDAQ:APGN) shares rose 10.46% to $0.95. The company's market cap stands at $23.4 million.
    • Chimerix (NASDAQ:CMRX) shares increased by 9.96% to $1.75. The company's market cap stands at $153.9 million. The company's, Q4 earnings came out today.

    Losers

    • Genelux (NASDAQ:GNLX) stock fell 19.5% to $13.6 during Thursday's pre-market session. The market value of their outstanding shares is at $320.5 million.
    • Cano Health (NYSE:CANO) stock fell 18.48% to $1.28. The market value of their outstanding shares is at $306.1 million. As per the news, the Q4 earnings report came out yesterday.
    • Xenetic Biosciences (NASDAQ:XBIO) stock fell 11.77% to $0.45. The market value of their outstanding shares is at $6.8 million.
    • Lucira Health (NASDAQ:LHDX) shares declined by 11.66% to $0.7. The market value of their outstanding shares is at $28.3 million.
    • Ontrak (NASDAQ:OTRK) shares decreased by 11.31% to $0.55. The market value of their outstanding shares is at $15.0 million.
    • Celularity (NASDAQ:CELU) shares declined by 10.44% to $0.65. The market value of their outstanding shares is at $94.8 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $APGN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APGN
    $ATXI
    $BPTS
    $BRTX

    CompanyDatePrice TargetRatingAnalyst
    Genelux Corporation
    $GNLX
    10/21/2025$16.00Buy
    Lake Street
    Genelux Corporation
    $GNLX
    10/29/2024$8.00Buy
    Guggenheim
    Genelux Corporation
    $GNLX
    8/28/2024$10.00Buy
    ROTH MKM
    Ontrak Inc.
    $OTRK
    12/5/2023$4.00Buy
    ROTH MKM
    Genelux Corporation
    $GNLX
    11/27/2023$35.00Buy
    H.C. Wainwright
    Genelux Corporation
    $GNLX
    9/12/2023$40.00Buy
    Maxim Group
    Cano Health Inc.
    $CANO
    8/11/2023Buy → Hold
    Jefferies
    Cano Health Inc.
    $CANO
    8/11/2023$4.00 → $0.80Buy → Neutral
    Citigroup
    More analyst ratings

    $APGN
    $ATXI
    $BPTS
    $BRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: Director Parks Diane L. was granted 30,000 shares, increasing direct ownership by 6% to 520,021 units (SEC Form 4)

    4/A - Celularity Inc (0001752828) (Issuer)

    1/15/26 4:15:32 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Director Ling Geoffrey M.D. was granted 19,231 shares, increasing direct ownership by 8% to 256,026 units (SEC Form 4)

    4/A - Celularity Inc (0001752828) (Issuer)

    1/15/26 4:15:29 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Director Diamandis Peter was granted 20,385 shares, increasing direct ownership by 5% to 394,150 units (SEC Form 4)

    4/A - Celularity Inc (0001752828) (Issuer)

    1/15/26 4:15:31 PM ET
    $CELU
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APGN
    $ATXI
    $BPTS
    $BRTX
    SEC Filings

    View All

    Avenue Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

    8-K - AVENUE THERAPEUTICS, INC. (0001644963) (Filer)

    2/23/26 4:06:15 PM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioRestorative Therapies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - BioRestorative Therapies, Inc. (0001505497) (Filer)

    2/13/26 8:40:45 PM ET
    $BRTX
    Managed Health Care
    Health Care

    SEC Form 424B4 filed by BioRestorative Therapies Inc.

    424B4 - BioRestorative Therapies, Inc. (0001505497) (Filer)

    2/13/26 9:48:15 AM ET
    $BRTX
    Managed Health Care
    Health Care

    $APGN
    $ATXI
    $BPTS
    $BRTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kranzler Jay D bought $1,250 worth of shares (500 units at $2.50), increasing direct ownership by 417% to 620 units (SEC Form 4)

    4 - AVENUE THERAPEUTICS, INC. (0001644963) (Issuer)

    10/1/24 4:15:13 PM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tyree James L bought 6,250 shares, increasing direct ownership by 181% to 9,710 units (SEC Form 4)

    4 - GENELUX Corp (0001231457) (Issuer)

    6/7/24 9:45:20 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Thomas John bought 2,500 shares, increasing direct ownership by 0.54% to 465,960 units (SEC Form 4)

    4 - GENELUX Corp (0001231457) (Issuer)

    6/7/24 9:45:16 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APGN
    $ATXI
    $BPTS
    $BRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on Genelux with a new price target

    Lake Street initiated coverage of Genelux with a rating of Buy and set a new price target of $16.00

    10/21/25 7:59:44 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Guggenheim initiated coverage on Genelux with a new price target

    Guggenheim initiated coverage of Genelux with a rating of Buy and set a new price target of $8.00

    10/29/24 6:26:41 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ROTH MKM initiated coverage on Genelux with a new price target

    ROTH MKM initiated coverage of Genelux with a rating of Buy and set a new price target of $10.00

    8/28/24 7:46:18 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APGN
    $ATXI
    $BPTS
    $BRTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioRestorative Expands Global Protection for ThermoStem®, a Potentially Longer-Lasting and Safer Cell-Based Alternative to GLP-1 Drugs

    GLP-1 drugs have captured global attention, but they come with limitations — tolerability issues, muscle mass loss, and potential cardiovascular risks. BioRestorative believes its cell-based therapeutic candidates may offer the potential for longer-lasting efficacy with improved safety and dosing advantages. MELVILLE, N.Y., Feb. 24, 2026 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a late stage clinical regenerative medicine innovator focused on stem cell-based therapies and products, today announced that IP Australia, the intellectual property branch of the Australian government, has allowed Patent Application No. 202026566

    2/24/26 8:30:00 AM ET
    $BRTX
    Managed Health Care
    Health Care

    Avenue Therapeutics Enters into Exclusive Worldwide License Agreement for ATX-04 for the Treatment of Pompe Disease

    ATX-04 is a selective β2-adrenergic agonist with human proof-of-concept data demonstrating improved muscle function and enhanced response to enzyme replacement therapy MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (OTC:ATXI) ("Avenue" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of therapies for rare and neurologic diseases, today announced that it has entered into an exclusive worldwide license agreement with Duke University for patents and know-how pertaining to ATX-04 (clenbuterol), a well-characterized small-molecule β2-adrenergic agonist, in clinical development for the treatment of Pompe disease. Pompe d

    2/23/26 8:00:00 AM ET
    $ATXI
    $FBIO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Genelux Corporation to Participate in Upcoming Conferences

    WESTLAKE VILLAGE, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced that the Company will participate in two upcoming conferences. Oppenheimer Healthcare Life Sciences Conference: Thomas Zindrick, President, CEO and Chairman of the Board; Matt Pulisic, Chief Financial Officer; and Dr. Jason Litten, Chief Medical Officer, will participate in a virtual fireside chat on Wednesday, February 25, 2026, at 11:20 a.m. ET.TD Cowen 46th Annual Health Care Conference: Thomas Zindrick, President, CEO and Chairman of the Board, and Matt Pulisic, Chief Financial Officer, will participate in a presentation on Monda

    2/18/26 8:00:00 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APGN
    $ATXI
    $BPTS
    $BRTX
    Financials

    Live finance-specific insights

    View All

    BioRestorative Therapies to Report Third Quarter 2025 Financial Results and Host Conference Call on November 12, 2025

    MELVILLE, N.Y., Nov. 05, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it will release its third quarter 2025 financial results after market close on Wednesday, November 12, 2025. Following the announcement, BioRestorative management will host a conference call to review the financial results and provide a business update. Third Quarter 2025 Results Conference Call Details: Date: Wednesday, November 12, 2025Time: 4:30 p.m. ETDomestic: 1-888-506-0062International: 1-973-528-0011Access Code: 464585 The call will also b

    11/5/25 4:30:00 PM ET
    $BRTX
    Managed Health Care
    Health Care

    BioRestorative Therapies Reports Second Quarter 2025 Financial Results and Provides Business Update

    MELVILLE, N.Y., Aug. 12, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today reported financial results for the second quarter ended June 30, 2025 and provided an update on its business. "We have continued to execute well across our business, including the achievement of key clinical program milestones, since the start of 2025," said Lance Alstodt, Chief Executive Officer of BioRestorative. "Moving forward, we remain focused on aggressively executing our growth strategy while carefully managing our resources, and see many potential value

    8/12/25 4:05:00 PM ET
    $BRTX
    Managed Health Care
    Health Care

    BioRestorative Therapies to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025

    MELVILLE, N.Y., Aug. 05, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a clinical stage regenerative medicine innovator focused on stem cell-based therapies and products, today announced that it will release its second quarter 2025 financial results after market close on Tuesday, August 12, 2025. Following the announcement, BioRestorative management will host a conference call to review the financial results and provide a business update. Second Quarter 2025 Results Conference Call Details: Date:Tuesday, August 12, 2025Time:4:30 p.m. ETDomestic:1-888-506-0062International:1-973-528-0011Access Code:436077 The call will al

    8/5/25 4:30:00 PM ET
    $BRTX
    Managed Health Care
    Health Care

    $APGN
    $ATXI
    $BPTS
    $BRTX
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    What Does the Recent Purchase at Air Transport Services Group Inc on Jun 7 Indicate?

    Recently, on June 7, 2024, Michael L Berger, a significant figure at Air Transport Services Group Inc, made a notable insider purchase. Berger bought $49,830 worth of shares, acquiring 3,996 units at a price of $12.47 per share. This transaction increased his direct ownership by 4% to 103,705 units as reported in the SEC Form 4 here. Examining other insider actions within the company can sometimes reveal intriguing patterns that might offer insights for investors. Looking back at previous transactions, we see a series of insider activities at Air Transport Services Group Inc: In March 2024, Dominick Jeffrey A. filed an SEC Form 4, indicating a notable transaction date in which actions were

    6/10/24 12:35:45 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APGN
    $ATXI
    $BPTS
    $BRTX
    Leadership Updates

    Live Leadership Updates

    View All

    Genelux Corporation Announces Appointment of Jason Litten, M.D., as Chief Medical Officer

    WESTLAKE VILLAGE, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) --  Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced the appointment of Jason Litten, M.D., as Chief Medical Officer, effective January 2, 2026. Dr. Litten will oversee all clinical development and medical strategy as the company advances Olvi-Vec through multiple upcoming pivotal milestones. "We are excited to welcome Jason, who is widely recognized for his strategic approach to clinical development and commitment to improving patient outcomes," said Thomas Zindrick, President, CEO, and Chairman of the Board. "He brings extensive experience in oncology drug development of innovati

    1/2/26 8:00:00 AM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BioRestorative Strengthens Commercial Leadership with Appointment of Crystal Romano as Head of Global Commercial Operations to Accelerate Growth of Cell-Based Product Portfolio

    MELVILLE, N.Y., Oct. 22, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. ("BioRestorative", "BRTX" or the "Company") (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced that Crystal Romano has joined its management team. In her role, Ms. Romano will be responsible for leading BioRestorative's global commercial operations and innovation. A seasoned executive with over 19 years of progressive leadership in the medical, aesthetics, and regenerative industries, Ms. Romano is recognized for her expertise in product development and innovation, commercialization, sales and account management, clinical and product training, a

    10/22/25 9:35:00 AM ET
    $BRTX
    Managed Health Care
    Health Care

    Genelux Corporation Reports Second Quarter 2025 Financial Results and Provides General Business Updates

    WESTLAKE VILLAGE, Calif., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Genelux Corporation (NASDAQ:GNLX), a late clinical-stage immuno-oncology company, today announced financial results for the second quarter of 2025 and provided general business updates. Momentum continued to build across the Company, as it looks forward to a series of key clinical readouts over the next year. These readouts are intended to further demonstrate the ability of Olvi-Vec to resensitize tumors to frontline platinum-based regimens. Genelux continues to advance Olvi-Vec toward potential registration in platinum-resistant/refractory ovarian cancer (PRROC) with topline data expected in the first half of 2026. Earlier this

    8/7/25 4:20:00 PM ET
    $GNLX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APGN
    $ATXI
    $BPTS
    $BRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Avenue Therapeutics Inc.

    SC 13D/A - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)

    11/15/24 4:05:50 PM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ontrak Inc.

    SC 13G/A - Ontrak, Inc. (0001136174) (Subject)

    11/14/24 4:24:03 PM ET
    $OTRK
    Misc Health and Biotechnology Services
    Health Care

    SEC Form SC 13G filed by Avenue Therapeutics Inc.

    SC 13G - AVENUE THERAPEUTICS, INC. (0001644963) (Subject)

    11/14/24 3:22:45 PM ET
    $ATXI
    Biotechnology: Pharmaceutical Preparations
    Health Care